TTM Family | DNano MetaBio has completed several tens of millions in Pre-A+ round financing
Hangzhou DNano MetaBio Technology Co., LTD. (hereinafter referred to as "DNano MetaBio"), has recently completed a Pre-A+ round financing of several tens of millions, exclusively invested by Panlin Capital. Previously, the company received multiple rounds of investment from many well-known investment institutions such as Taiyu Capital, TTM Capital, Jiliuling Fund, and Muren Capital within a year.
Hangzhou DNano MetaBio Technology Co., LTD. (hereinafter referred to as "DNano MetaBio"), a company based on a next-generation DNA self-assembling drug nanocarrier platform, has recently completed a Pre-A+ round financing of several tens of millions, exclusively invested by Panlin Capital. Previously, the company received multiple rounds of investment from many well-known investment institutions such as Taiyu Capital, TTM Capital, Jiliuling Fund, and Muren Capital within a year. This financing will further consolidate the company's technological advantages in the field of DNA nanocarriers and promote the research and development of multiple pipelines for tumors, metabolic diseases, vaccines, and more.
Dr. Baoquan Ding, founder and chief scientist of DNano MetaBio, obtained his Ph.D. in Chemistry from New York University in September 2006, under the supervision of Professor Nadrian Seeman, the founding father of DNA nanotechnology. Dr. Ding is one of the first focusing on the research of nucleic acid self-assembling drug carriers. In 2010, Dr. Ding returned to China and joined the National Center for Nanoscience and Technology, where he began exploring the application of nucleic acid self-assembly technology in drug delivery. He has published over a hundred articles in top international journals such as Nature Materials, Nature Biotechnology, and Nature Communications, and his related work was selected as one of the top ten scientific advances in China in 2018 and as a leading technology in "Science and Innovation China" in 2020.
Currently, the company has established a research and development, process development, and quality management team of dozens of people, fully promoting pipeline development. Utilizing the advantages of carrier targeting technology, DNano MetaBio has launched pipeline layout in the fields of tumor, metabolic diseases, and vaccines, with delivery carriers having obtained safety data at different dimensions at the animal level, and the core pipeline has progressed to the PCC confirmation stage.
About Hangzhou DNano MetaBio Technology Co., LTD.
Hangzhou DNano MetaBio Technology Co., LTD. was established in 2022. The company focuses on the design of nucleic acid nanocarriers and is one of the earliest teams in the world to apply this technology to drug delivery and conduct in vivo biological experiments. The company is oriented towards building innovative drugs that meet clinical needs, with the mission of "innovating biotechnology to safeguard life and health." It develops nucleic acid nanocarriers to achieve precise, efficient, and safe delivery of various drugs, including chemotherapy drugs, protein drugs, and nucleic acid drugs in the human body. Especially in the delivery of small nucleic acid drugs, the company's newly developed drug delivery platform—DNA nanocarriers—demonstrates great potential for both safety and targeting, promising to address the industry's pain points in extrahepatic targeting delivery of small nucleic acid drugs.
About XinThera Pharmaceuticals, Inc
XinThera was established in 2021, based on a structural drug discovery platform, focusing on fast follow small molecule drug development for First-in-Class and blockbuster drugs. Since receiving seed round financing in February 2021, the company has rapidly developed its business. The company was co-founded by Dr. Qing Dong, former Chief Scientist at Hengrui Pharmaceuticals, and seasoned entrepreneurs who had successfully started four companies in the U.S. and built several NASDAQ-listed companies. The R&D team consists of senior oncology and immunology experts with over twenty years of experience in new drug development, having successfully developed seven marketed drugs and a dozen clinical candidates.
Who we are
TTM Capital is a professional investment institution focused on early-stage investments in the healthcare sector. The founding and managing team been involved in the medical and biotechnology fields for many years, with a background in medical investments from top domestic funds to full industry chain experience from globally leading multinational pharmaceutical companies. TTM Capital mainly focuses on high-quality investment opportunities in the fields of biopharmaceuticals, medical devices and in vitro diagnostics driven by cutting-edge technology, focusing on segmented tracks with significant advantages, focusing on the global medical market and the "unmet needs" of patients. Persist in empowering and creating synergistic value for invested companies, jointly promote medical innovation, and create value for society.
